Skip to main content

Table 4 Meta-regression Analysis

From: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Outcome Predictor p-value
  > 3 sites No adjuvant Chemo Visceral site Hormonal Receptors Negative Prior taxanes Prior Anthra
PFS 0.032 0.00013 0.03 0.009 0.96 0.019
OS 0.99 0.18 0.56 0.66 0.45 0.91
  1. Anthra (A): anthracyclines PFS: progression free survival; OS: overall survival.